Squamous cell carcinoma of the oral cavity in nonsmoking women: A new and unusual complication of chemotherapy for recurrent ovarian cancer?

Oncologist

Volumn 17, Issue 12, 2012, Pages 1541-1546

  Cannon, Timothy L ^a   Lai, Dominic W ^a   Hirsch, David ^a   Delacure, Mark ^a   Downey, Andrea ^a   Kerr, Alexander R ^a   Bannan, Michael ^a   Andreopoulou, Eleni ^a   Safra, Tamar ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Head and neck secondary malignancies; Oral SCC as side effect; Ovarian cancer; Pegylated liposomal doxorubicin; Secondary malignancy

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PACLITAXEL; PROTEIN P16; TOPOTECAN; VELIPARIB;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DYSPLASIA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; ORAL BIOPSY; ORAL MUCOSITIS; OVARY CANCER; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK FACTOR; TREATMENT DURATION; WART VIRUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DIAGNOSIS, ORAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; MOUTH NEOPLASMS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RISK FACTORS;

EID: 84871566282     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0216     Document Type: Article

References (24)

1. Boffetta P, Kaldor JM. Secondary malignancies following cancer chemotherapy. Acta Oncol 1994;33:591-598.
2. Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes. Ann Oncol 1992;3:107-111.
3. Azarova AM, Lyu YL, Lin CP et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A 2007;104:11014-11019.
4. De S, Ghosh S, Mondal D et al. Osteosarcoma of the mandible-second cancer in a case of Hodgkin's lymphoma post-chemotherapy. J Cancer Res Ther 2010;6:336-338.
5. Khadwal A, Biswas G, Arora B et al. Primitive neuroectodermal tumor (PNET) as second malignancy after treatment of Hodgkin's disease. Indian J Pediatr 2006; 73:437-438.
6. Weinel S, Malone J, Jain D et al. Leukaemia cutis in a patient treated for breast cancer. Australas J Dermatol 2009;50:52-55.
7. Moser EC, Noordijk EM, van Leeuwen FE et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica 2006;91:1481-1488.
8. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
9. Martin-Carbonero L, Palacios R, Valencia E et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008;47:410-417.
10. Andreopoulou E, Gaiotti D, Kim E et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007;18:716-721.
11. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-3329.
12. Muggia F, Cannon T, Safra T et al. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer. J Natl Cancer Inst 2011;103:160-161.
13. Cannon TL, Muggia F, Hirsch D et al. Multiple cases of squamous cell carcinoma of the tongue and oral cavity in patients treated with long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer. J Clin Oncol 2011;29(suppl; abstr 5557).
14. Andreopoulou E, Chen T, Liebes L et al. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: Potential for consolidation in ovarian cancer. Cancer Chemother Pharmacol 2011;68:457-463.
15. Kadouri L, Hubert A, Rotenberg Y et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007;44:467-471.
16. Jaworowska E, Tarnowska C, Lubinski J et al. Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers. Anticancer Res 2009;29: 2703-2705.
17. Safra T, Borgato L, NicolettoMOet al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 2011;10: 2000-2007.
18. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 1996;355:59-70.
19. Chibber R, Ord MJ. The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds:Acomparison with cisplatin. Eur J Cancer Clinical Oncol 1989;25:27-33.
20. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003;42: 419-436.
21. Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: First step to induce the palmarplantar erythrodysesthesia syndrome? Ann Oncol 2005; 16:1210-1211.
22. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-254.
23. Babu K, Murthy KR, Krishnakumar S. Two successive ocular malignancies in the same eye of a HIVpositive patient: A case report. Ocul Immunol Inflamm 2010;18:101-103.
24. Kwon SI, Chung YS, Kim YJ. Squamous cell carcinoma of the conjunctiva invading the orbit in a non-Hodgkin lymphoma. Jpn J Ophthalmol 2009; 53:650-651.